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Recent epidemiologic investigations have identiﬁed an association between type 2 dia-
betes and uric acid kidney stones. This association was more apparent in women than in
men. In this paper, we show through powder neutron diffraction that particle sizes of uric
acid kidney stones were signiﬁcantly different between male and female patients
(84.7± 5.3 vs. 140.2± 6.7 nm, p¼ 0.000003). Interestingly, when type 2 diabetes appeared,
this structural difference between male and female vanished (76.1± 3.9 vs. 78.8± 4.2 nm,
not signiﬁcant). Thus, the complete set of structural data is in line with observations
regarding epidemiological data. Some explanations based on supersaturation are
discussed.
© 2015 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Signiﬁcant changes in dietary habits and lifestyle during
the past thirty years have induced a considerably increased
incidence of obesity, metabolic syndrome and type 2 dia-
betes throughout the world [1e7]. At the same time, uro-
lithiasis relentlessly increased [8e17] affecting now up to
15% of the population in industrialized countries [3,18,19].
Two recent epidemiological investigations [20,21] point
out an intimate correlation between these public health
problems, namely obesity, type 2 diabetes and urolithiasis.Daudon).
ed by Elsevier Masson SAS.Unfortunately, the chemical nature of the stones was not
recorded. At this point, we should recall that the chemistry
of such concretions is quite complex, involving various
inorganic and/or organic compounds: Ca oxalate (70% of
the cases), Ca and Mg phosphates (15%), uric acid (10%) and
other phases (5%) which can be organized into different
crystalline phases [22e27]. The chemical composition,
colour and morphology constitute key information which
helps in the determination of the associated pathology
[28e41]. As suggested by recent reports, calcium oxalate
and uric acid (UA) stones may be favoured by metabolic
disorders associated with metabolic syndrome or type 2
diabetes [42e44]. However, the dramatic increase in the
proportion of UA stones observed in stone-formersThis is an open access article under the CC BY-NC-ND license (http://
Table 1
Estimated particle size (±standard deviation) in nm of UAA crystals
determined through PND for non-diabetic male patients.
Sample Localisation e Age
(years)
Estimated size of UAA crystals
(±standard deviation) in nm
Non diabetic
males
Type IIIa stones
Non diabetic
males
Type IIIb stones
1-14222 L 65 (2)
2-26297 L e 79 83 (7)
3-33096 L e 69 76 (7)
4-39613 L e 91 97 (3)
5-9291 L e 78 88 (2)
6-35866 U e 61 81 (4)
7-39514 U e 34 109 (3)
8-40161 U e 66 69 (2)
9-43605 U e 60 73 (3)
10-46063 U e 44 73 (3)
11-56883 U e 51 112 (5)
12-55521 U e 44 81 (3)
13-46015 L e 67 93 (3)
L: lower urinary tract; U: upper urinary tract.
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tween insulin resistance and UA stone formation in both
male and female patients. From a medical point of view,
several pathophysiological arguments may explain the
propensity of stone-formers with type 2 diabetes to pro-
duce UA stones. Metabolic syndrome alters cell sensitivity
to insulin and renal acidebase metabolism, resulting in a
lower urine pH and an increased risk of uric acid stone
disease [3,45]. With respect to gender, some authors have
observed that women had a stronger association of dia-
betes with the risk of prevalent kidney stones than did
men, and that the former appear especially at risk of
forming UA stones [46]. Taking advantage of the large
number of patients referred to our hospital laboratory, a
more precise relationship has been established between UA
or 2,6,8-trioxypurine (C5H4N4O3) kidney stones and pa-
thology. The complete set of data shows that the proportion
of UA stones is strikingly higher in stone formers with
diabetes than those without [47,48], which is in agreement
with the data reported by other authors [49].
The aim of this paper is to provide a structural
description of uric acid stones in order to determine
whether diabetic and non-diabetic patients form similar
urinary stones. Also, the gender and age of the patients,
which seem to be signiﬁcant parameters, are taken into
account in this study. For the sake of clarity, we use the
terms ‘nanocrystals’ and ‘crystallites’ following Van
Meerssche & Feneau-Dupont [50] in order to deﬁne the
structural hierarchy of these mineral concrements [51e56].
In this simpliﬁed scheme, a collection of nanocrystals (each
measuring about one hundred nanometres) constitutes a
crystallite (measuring some tens of micrometres). Struc-
tural characteristics regarding the nanocrystals are pro-
vided by powder neutron diffraction (PND) [57e60]. The
fact that the neutron interacts only weakly with the stones
and thus can penetrate deeply into the bulk [61] offers an
excellent opportunity for measuring the average size of the
nanometre scale nanocrystals made of light elements as
shown for other species identiﬁed in kidney stones
[62e66]. Regarding crystallites, a precise description of
their shape and their structural organization has been
performed through Scanning Electron Microscopy (SEM)
[67].
2. Materials and methods
2.1. Samples
Regarding UA urinary stones, the classiﬁcation per-
formed through their morphology as well as by Fourier-
Transform InfraRed (FT-IR) spectroscopy [68,69] distin-
guishes two morphological types, namely IIIa and IIIb, each
being related to speciﬁc conditions [28]. For example, the
surface of IIIa type stones is homogeneous, smooth or
slightly embossed. Such IIIa stones are mainly associated
with stasis with a moderately low urinary pH and are
commonly observed in the bladder of elderly men with
prostate hypertrophy. At the mesoscopic scale, these stones
are characterized by a very compact inner structure made
of concentric layers with a radial organization of the crys-
tals. In contrast, IIIb stones are essentially related tohyperuricosuria and/or very acidic urine as observed in the
metabolic syndrome and type 2 diabetes. Their surface is
heterogeneous, rough or porous and their colour varies
from whitish to brownish-red. Their cross-section exhibits
a loose, porous, and poorly organized structure.
The stones selected for the present study fulﬁlled the
following criteria: (1) the sample size of the stonewas large
enough to perform all the analytical methods including
stereomicroscopy examination, FT-IR analysis and there-
after SEM and PND measurements; (2) clinical data
regarding the patient's age and diabetes status, (3) the
anatomical location of the stone at the time of removal
(upper urinary tract: kidney, ureter; or lower urinary tract:
bladder).
UA stones from 43 patients (24 males, 19 females) were
investigated (Tables 1e3). All the stones were mainly
composed of uric acid anhydrous (UAA). The mean age of
the patients was 58.8± 2.8 for females and 66.9± 2.5 years
for males (p¼ 0.036). Among these patients, 22 (11 males,
11 females) suffered from type 2 diabetes (Table 3). A
preliminary analysis was carried out at the hospital using a
stereomicroscope for morphological typing and an FT-IR
spectrometer to determine accurate stone composition.
All statistical comparisons including UAA crystal size
versus the patient's sex and age, the anatomical location of
the stone at the time of removal and the stone morphology
were performed using ANOVA or a chi square test when
appropriate. Data analysis was performed with the NCSS
statistical package (J. Hintz, Gainesville, FL). A p value less
than 0.05 was considered as statistically signiﬁcant.2.2. Investigation tools
An FEI/Philips XL40 environmental SEM (ESEM) equip-
ped with an energy-dispersive X-ray spectrometer was
used for sample characterization. An important feature of
the ESEM compared to a conventional SEM is the fact that
non-conductive materials can be imaged without any
conductive coating, which permits a direct observation
Table 2
Estimated particle size (±standard deviation) in nm of anhydrous uric acid
crystals determined through PND for non-diabetic female patients
Sample Localisation e Age
(years)
Estimated size of UAA crystals
(±standard deviation) in nm
Non diabetic
females
Type IIIa stones
Non diabetic
females
Type IIIb stones
14-26093 U e 48 144 (13)
15-33951 U e 70 107 (8)
16-37223 U e 64 185 (14)
17-42754 U e 62 143 (10)
18-24808 U e 34 146 (8)
19-25765 U e 72 130 (5)
20-30297 U e 49 110 (5)
21-38727 U e 56 155 (10)
U: upper urinary tract.
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with a gaseous secondary electron detector, at an acceler-
ating voltage of 20 kV and awater pressure of 0.4 torr in the
chamber. This low pressure was used to maintain a high
spatial resolution for the X-ray analysis by minimizing the
scattering of the primary electron beam. Also, a Zeiss
SUPRA55-VP type scanning electron microscope was used
for microstructure observation. This ﬁeld effect gun mi-
croscope operates at 0.5e30 kV. High resolution observa-
tions were obtained using two secondary electron
detectors: an in-lens and an EverharteThornley detector.
Neutron diffraction diagrams were collected on a G4.1
two-axis multidetector powder diffractometer [70]
installed at the cold-source beamline of the Orphee
reactor (Saclay, France). This beamline was equipped with aTable 3
Estimated particle size (±standard deviation) in nm of UAA crystals
determined through PND for diabetic patients
Sample Localisation e Age
(years)
Estimated size of UAA crystals
(±standard deviation) in nm
Diabetic Males Diabetic Females
22-4021 U e 60 65 (4)
23-5432 U e 79 84 (3)
24-19381 L e 79 87 (3)
25-26273 L e 76 83 (3)
26-43019 U e 50 98 (5)
27-44050 U e 59 62 (4)
28-44336 U e 79 74 (2)
29-46893 U e 73 80 (3)
30-56617 L e 73 78 (5)
31-57420 L e 60 59 (5)
32-59315 L e 76 66 (6)
33-15216 U e 62 76 (2)
34-30951 U e 61 76 (4)
35-17619 U e 76 87 (3)
36-24951 U e 66 68 (5)
37-26115 U e 56 90 (4)
38-47159 U e 60 63 (4)
39-66145 U e 61 111 (3)
40-57052 U e 41 71 (3)
41-58253 U e 61 82 (3)
42-59028 U e 60 63 (2)
43-38011 U e 58 80 (2)
L: lower urinary tract, U: upper urinary tract.two-axis powder diffractometer with a vertically focussing
pyrolytic graphite monochromator and an 800-cell multi-
detector covering an 80 2q range (step 0.1 between
2 cells). Neutron diffraction patterns were collected at room
temperature between 7 and 87 using a wavelength of
2.4226 Å, with an acquisition time of the order of a few
hours, the exact value depending on the samples. This
particular experimental setup offers the opportunity of
determining the size of nanocrystals in a range between 5
and 200 nm.
The phase identiﬁcation, lattice constant determination
and quantitative phase analysis were performed through
Rietveld reﬁnement using the Fullprof program [71] based
on the crystallographic structure of two reference com-
pounds, namely uric acid dihydrate (UAD), C5H2N4O3∙2H2O
[72] which is orthorhombic with a space group Pnab
(a¼ 0.7409(1) nm, b¼ 1.7549(3) nm, c¼ 0.6332(1) nm) and
UAA (C5H2N4O3), a monoclinic structure with a space group
P21/a with four molecules in a unit cell of dimensions
a¼ 1.4464 nm, b¼ 0.7403 nm, c¼ 0.6208 nm, b¼ 65.10
[73].
The particle size is determined by extracting the
broadening of Bragg peaks of the kidney stone atomic
structure due to their ﬁnite size [74]. The lower the size, the
more the peaks are broadened in comparison to their
normal width linked to the resolution function of the
neutron diffractometer. We have taken a model of isotropic
broadening with a Thomson-Cox-Hastings proﬁle peak
function. With the Fullprof program, we reﬁne a Y Lor-
entzian broadening parameter simply linked to the mean
particle size of the compound (29). Taking into account the
experimental resolution of the beamline G4.1 as well as the
signal to noise ratio, the size of the UAA crystals is given by
8.9/Y nm. In this work, only the particle size of the major
component, namely UAA, is discussed.
3. Results
Uric acid stones may present mainly two different
morphological aspects at the macroscopic scale as illus-
trated in Fig. 1.
The structural characteristics at the mesoscopic scale
obtained by ESEM are presented in Fig. 2. Fig. 2(a) displays
the microstructures of a stone belonging to the IIIa
morphological type and Fig. 2(b) shows a stone exhibiting a
IIIb type.
In Fig. 2(a), a preferential orientation of the crystallites is
clearly observed at the 50 mm scale. In a stone corre-
sponding to the IIIb type of our classiﬁcation, no prefer-
ential orientation of the crystals is seen: as an example, a
collection of crystallites with random orientation is visu-
alized for the sample as shown in Fig. 2(b) at approximately
the same scale. These results are in line with the morpho-
logical classiﬁcation used in routine practice, in which this
type of stone exhibits an unorganized macroscopic struc-
ture. The distribution of the stones according to their
anatomical location showed that type IIIa calculi weremore
frequent in the bladder (57.9%) while type IIIb calculi were
more frequent in the upper urinary tract (95.8% of cases,
p< 0.0001). However, from the complete set of ESEM im-
ages, it was not possible to deﬁne any structural differences
Fig. 1. Uric acid calculi. A) surface of a type IIIa stone. The surface is smooth and homogeneous; B) section of a type IIIa stone exhibiting a well organized
structure; C) surface of a type IIIb stone. The surface is heterogeneous, locally embossed, rough or porous; D) section of a type IIIb stone exhibiting a poorly
organized structure with porous areas. Bars¼ 3 mm.
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non-diabetic patients.
The structural investigation at the nanometre scale was
performed through PND. PND is a non-destructive tool
which has the ability to penetrate deeply inside most
materials. The estimated nanocrystal size is thus an
average over all nanocrystals present in the kidney stone.
We also take advantage of the high sensitivity of the
neutrons to light elements, namely hydrogen, oxygen and
carbon. Fig. 3 presents a typical PND spectrum of uric acid
anhydrous.
Uric acid stones may be formed either in the upper
urinary tract or in the bladder, particularly in older male
patients with a benign prostate hypertrophy responsible
for urine stasis [75]. Comparison of the size of UAA crystals
according to the stone location within the urinary tract
showed a tendency toward smaller crystals in the lower
urinary tract: 78.7± 8.0 nm vs. 96.2± 5.0 nm for stones
developed in the kidney (p¼ 0.07). Another unexpected
variation in the size of UAA crystals was observed as a
function of the patient's age. The mean crystal size
decreased from 106.2± 7.3 nm in subjects aged below 60
years to 87.0± 6.4 nm (p¼ 0.06) in subjects aged above 70
years.We report in Figs. 4 and 5 the average size of the
nanocrystals measured for non-diabetic male and female
patients (Fig. 4: samples 1 to 13 for male patients; Fig. 5:
samples 14 to 21 for female patients). Numerical values are
reported in Tables 1 (males) and 2 (females).
For males, the average size was 79.2± 3.9 nm for IIIa
calculi and 82.6± 4.3 nm for IIIb calculi (p¼ 0.56), while for
females, the average size was 121.8± 14.4 nm for IIIa and
96.7± 9.8 nm for IIIb calculi (p¼ 0.18). Thus, no difference
was found in the crystal size between IIIa and IIIb types. In
contrast, the average size for the whole series of UA stones
from male patients was 80.7± 5.3 nm while for females it
was 104.7± 6.0 nm (p¼ 0.0049), a strong difference which
suggests that the biochemical environment is very different
according to the gender of the patient.
Interestingly, in diabetic patients (Table 3, Fig. 6), the
mean size of UAA crystals was signiﬁcantly lower than in
non-diabetic patients (77.5± 5.3 nm vs. 105.8± 5.4 nm,
p¼ 0.0006). Indeed, the difference was essentially the
result of a change in the crystal size between non-diabetic
and diabetic females (140.2± 6.8 nm vs. 78.8± 5.8 nm,
respectively, p¼ 0.000003), while the crystal size remained
essentially unchanged in male patients (84.7± 3.7 nm in
non-diabetic vs. 76.0± 4.1 nm in diabetic subjects, p¼ 0.2).
Fig. 2. (a) ESEM image of a IIIa sample showing a preferential orientation of
the crystallites, (b) a random orientation of crystallites observed for a IIIb
stone (sample N10416) and (c) a speciﬁc structure corresponding to the
phase conversion between the two uric acid species (from dihydrate to
anhydrous).
Fig. 3. Final reﬁnement, with experimental (), calculated () and different
PND patterns of the sample N 40161. Tick marks below the proﬁles indicate
the peak positions of allowed Bragg reﬂections for UAA.
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In this study, two different analytical approaches were
applied to stone analysis, ﬁrst ESEM for studying the inner
structure and crystallite organizationwithin the stones, and
second, PND for measuring the mean size of UAA crystals.
ESEM has been used as an investigation tool in
numerous in vitro as well as in vivo investigations [76].
The former helps to describe the morphology of crystals as
a function of supersaturation [77], phase conversion pro-
cesses [78,79], or the effect of uric acid seeds on calcium
oxalate formation [80]. Regarding in vivo studies, this
technique can reveal the presence of bacteria at the sur-
face of uroliths [81]. Recently, a close relationship wasobserved between the presence of bacterial imprints,
indicative of a past or current urinary tract infection, and
both the presence of amorphous carbonated calcium
phosphate (or whitlockite) and a high carbonate concen-
tration in calculi made of carbapatite [82]. Such micro-
scopic investigations can play a key role in the diagnosis of
major genetic pathologies, revealing a particular crystal-
line structure in whewellite stones resulting from primary
hyperoxaluria type 1 when compared to the common type
of whewellite stones [33]. Finally, we use this technique to
understand the genesis of Randall's plaque, a deposit of
apatite at the surface of the papilla which serves as a nidus
for calcium oxalate calculi and also to determine the cal-
cium oxalate calculi growth process at the surface of
Randall's plaque [83]. In the present study, we found
correlations between the organization of crystallites of
uric acid at the mesoscopic scale and macroscopic char-
acteristics of the stones as previously reported for other
types of stones. We found a statistical difference between
IIIa and IIIb stones according to their anatomical location,
IIIa stones being more frequent in the bladder while IIIb
stones were essentially formed in the upper urinary tract.
However, we failed to ﬁnd differences between ESEM
images and clinical data.
From a clinical point of view, uric acid stones account for
10e20% of urinary calculi in western countries (10% in
France) and may be related either to low urine pH or
increased excretion of uric acid. Recent epidemiological
studies have clearly shown a relationship between over-
weight, type 2 diabetes and the risk of developing neph-
rolithiasis [20,21,84]. Other studies underlined an increased
risk of uric acid nephrolithiasis as a consequence of meta-
bolic changes in overweight and diabetic patients
[49,85,86]. In our experience, pathological changes related
Fig. 4. Nanocrystal sizes of UAA urinary stones from non-diabetic male
patients (see Table 1).
Fig. 5. Nanocrystal sizes of UAA urinary stones from non-diabetic female
patients (see Table 2).
Fig. 6. Nanocrystal sizes of UAA urinary stones from diabetic male (from 22
to 32 in black square) and female (from 33 to 43, white diamonds) patients.
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lithiasis since about 2/3 of all uric acid stones are associated
with the metabolic syndrome or type 2 diabetes [87].
Although the stone composition was considered in some
studies [44,48,85] the structural characteristics of the
stones were never assessed. The aim of our study was toseek possible structural differences at the nanometre and
mesoscopic scale in uric acid stones developed in non-
diabetic and diabetic male and female patients. At the
mesoscopic scale, we were able to differentiate two main
types of UA stones according to their crystallite organiza-
tion. These results are in close agreement with previous
descriptions by other authors [79]. These authors also
deﬁned two kinds of uric acid stones: type I includes stones
with a small central core and a compact columnar uric acid
anhydrous shell while type II is associated with porous
stones without inner structure. Types I and II of this clas-
siﬁcation correspond to types IIIa and IIIb stones, respec-
tively in our own classiﬁcation. We found such a structural
organization in both male and female patients. Type IIIb
stones appeared clearly more frequent in the upper urinary
tract while IIIa stones were more frequent among bladder
calculi. Of note, in our series, all bladder stones were from
male patients. No structural difference was found between
UA stones from male and female patients or between
stones from diabetic and non-diabetic patients.
In contrast, one of the striking points of the PND results
was that the crystal size of uric acid stones was signiﬁcantly
lower in diabetic patients (77.5± 5.3 nm vs. 105.8± 5.4 nm,
p¼ 0.0006). As previously reported, overweight and obese
conditions, one of the main anthropometric characteristics
of patients suffering a metabolic syndrome with an insulin
resistance, are often associated with an increased risk of UA
stones [21,34,85,86]. The main explanation is that insulin
resistance could be responsible for a low urine ammonium
excretion and a high net acid excretion inducing a decreased
urine pH [86]. An inverse correlation between body weight
and urine pH has been recently reported [45] and also be-
tween HbA1c level in blood and urine pH in patients with
M. Daudon et al. / C. R. Chimie 19 (2016) 1527e1534 1533type 2 diabetes [88]. Insulin resistancemay also result from a
mitochondrial dysfunction, which progressively appears
with increasing age, explaining, together with increased
body mass index (BMI) related to age, the higher proportion
of uric acid observed in elderly patients [89,90].
A low urine pH is the main factor explaining high UA
supersaturation in urine and, in clinical practice, acidic
urine was the main disorder explaining UA stone formation
[91]. These features can explain the high proportion of UA
stones in older patients [92]. In accordance with crystalli-
zation rules [93], a high UA supersaturation could be
responsible for a high number of UA nuclei leading to a
smaller size of the observed crystals. Surprisingly, we found
a striking difference in the crystal size between male and
female patients. Thus, the difference in crystal size
observed between diabetic and non-diabetic patients
appeared to be essentially related to the patient's sex. A
hypothesis is that such a difference between male and fe-
male patients could be related to basic differences in urine
supersaturation regarding uric acid. From an epidemio-
logical point of view, males are well known to be more
prone to developing UA stones than females, the risk
increasing with age [94e97].
As shown in Fig. 7, although male and female patients
exhibit an increasing proportion of UA stones related to
their BMI, only male patients appear to be especially sus-
ceptible to that risk.
A possible explanation could be a difference in urine pH
between males and females. In our experience, based on
urinary pH measurement in more than 20,000 urine sam-
ples, females exhibit a signiﬁcantly higher urine pH than
males (6.27± 0.02 vs. 6.14± 0.01, p< 0.0001). This experi-
mental fact suggests that in patients suffering a metabolic
syndrome, females are less prone than males to produce
very acidic urine, explaining their lower propensity to form
uric acid stones.
In the case of type 2 diabetes, the structural difference in
crystal size between males and females vanishes. Indeed,
amongmale stone formers, the increased risk of developing
UA stones in the case of type 2 diabetes appeared limited
when compared to overweight non-diabetic patients; asFig. 7. Proportion of UA stones in male and female non-diabetic patients as a
function of their body mass index (BMI, kg/m2).previously shown, the proportion of uric acid stones in
obese male patients (BMI 30 kg/m2) was 28.7% [48] and
moderately increased to 33.2% in diabetic patients [46]. In
contrast, in female stone formers, the proportion of uric
acid stones increased from 6.1% in the case of normal BMI to
17.1% in obese patients, always remaining signiﬁcantly
lower than in males. Thus, as shown in Fig. 7, female pa-
tients seem to be less susceptible to that risk than are male
patients, which is in agreement with previous data [48].
The striking point of our previous studies was that the risk
of producing uric acid stones among diabetic female stone
formers was very high (42.5%) [44]. Such observations
suggest that UA supersaturation could be higher in diabetic
female patients, while it could be lower in non-diabetic
ones, resulting in a smaller number of UAA crystals with
a larger size than that observed in male patients. A lower
supersaturation also decreases the crystallization rate,
inducing a lower risk of crystal retention in the urinary
tract [93]. This hypothesis could explain the lower preva-
lence of UA stones in non-diabetic women, including obese
patients. In contrast, in the case of type 2 diabetes, female
stone-formers are especially at risk of UA stones, due to
high urine UA supersaturation, as suggested by epidemio-
logical data [44] and by PND measurements showing a
signiﬁcant decrease in UA crystal size. Perhaps, in addition
to low urine pH, these patients have a higher excretion rate
of uric acid in urine than do male subjects and they reach
an especially high degree of uric acid supersaturation.
Further studies are required to conﬁrm this hypothesis.
5. Conclusion
The complete set of PND data showed that the crystal
size of UA kidney stones was signiﬁcantly different be-
tween male and female patients. Moreover, type 2 diabetes
altered this difference. For non-diabetic patients, the
average size of UAA nanocrystals was 85 nm for male and
140 nm for female patients (p< 105). For diabetic patients,
the average size of UAA crystals was 76.0 nm for male
subjects and 78.8 nm for female subjects (p¼ 0.6). Expla-
nations based on differences in urine supersaturation may
help to explain the observed differences, but further studies
are needed to understand more precisely these structural
modiﬁcations of UA kidney stones, which is in line with
similar observations regarding epidemiological data.
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